CA
NZ
UK
AU
IND
US
Phase 3 Trial Results Strengthen Clinical Positioning in Cardiovascular Markets
RESOLVE Trial Data Signals Dose-Dependent Clinical Improvement
Strong Clinical Efficacy Supports Regulatory Momentum
Q2 FY2026 Performance: U.S. Weakness Drives Revenue Decline
Q1 2026 Earnings Beat Expectations Despite Modest Revenue Growth
Revenue Growth Outpaces Expectations in Q1 2026 Results
Strategic Capital Raise and Balance Sheet Implications
Capital Structure Simplification Through Royalty Buyback
Esperion Therapeutics (NASDAQ:ESPR) jumped sharply after the developer of the LDL-cholesterol-lowering therapies Nexletol and Nexlizet (bempedoic acid and the bempedoic acid/ezetimibe fixed-dose combination) agreed to be taken private by Paris-based healthcare specialist Archimed in a transaction with an enterprise value of up to $1.1bn. …
Bristol-Myers Squibb (NYSE:BMY) sits at one of the most closely watched inflection points in large-cap pharma. The stock is in focus because the company is simultaneously managing the loss of exclusivity (LOE) on several legacy blockbusters, integrating a transformativeAcquisitionin neuroscience, executing a multibillion-dollar cost-savings …
Please wait processing your request...